Novo Nordisk: The Case For Predictability In Earnings

26-08-2014 Seeking AlphaComments (0)

By QE Holdings:

Denmark is famous for producing bacon - lots of bacon. In fact, with a pig population of 18.9 million (in 2011), there are more than three times as many pigs as there are people in Denmark, so there's plenty enough of the stuff to go around. But while the Danes are busy handing out bits of porky goodness with one hand, they're even busier handing out insulin with the other. Not-so-famously, Denmark is also home to Novo Nordisk (NYSE:NVO), the world's largest player in the diabetes care market. With the share price up more than 20% year-to-date, Novo Nordisk has now surpassed GlaxoSmithKline (NYSE:GSK) in market capitalization.

The short story about earnings

Over the past ten years, Novo Nordisk's annualized growth rate of earnings has been nearly 21%. Over the past five years, it has been closer to 25%. The impressive constancy of this growth is evident in

Complete Story »

Read more on Seeking Alpha

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top